CRBP - Corbus Pharmaceuticals Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Norwood,
United States
Type: Equity
CRBP price evolution
CRBP
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3.54 | $24.36 | $14.77 | $14.39 |
| Short term investments | $123.34 | $106 | $7.18 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $160.89 | $148.31 | $121.7 | $23.55 |
| Long term investments | ||||
| Property, plant & equipment | $2.9 | $3.28 | $3.66 | $4.04 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.67 | $4.05 | $4.73 | |
| Total investments | $123.34 | $106 | $7.18 | |
| Total assets | $164.17 | $151.98 | $125.74 | $28.27 |
| Current liabilities | ||||
| Accounts payable | $2.89 | $1.15 | $2.08 | $3.18 |
| Deferred revenue | ||||
| Short long term debt | $12.34 | $14.43 | $17.65 | |
| Total current liabilities | $11.63 | $23.98 | $25.92 | $31.89 |
| Long term debt | $2.46 | $2.86 | $3.24 | |
| Total noncurrent liabilities | $2.46 | $2.86 | $3.28 | |
| Total debt | $14.8 | $17.29 | $20.88 | |
| Total liabilities | $13.67 | $26.44 | $28.78 | $35.18 |
| Shareholders' equity | ||||
| Retained earnings | -$467.36 | -$453.58 | -$443.58 | -$436.68 |
| Other shareholder equity | $0.21 | -$0.39 | -$0.33 | -$0 |
| Total shareholder equity | $125.54 | $96.97 | -$6.9 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.39 | $3.81 | $25.68 | $86.45 |
| Short term investments | $7.18 | $42.19 | $72.64 | |
| Net receivables | $0.96 | |||
| Inventory | ||||
| Total current assets | $23.55 | $60.18 | $100.2 | $92.07 |
| Long term investments | ||||
| Property, plant & equipment | $4.04 | $5.5 | $7 | $9.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $4.73 | $6.13 | $7.53 | $10.22 |
| Total investments | $7.18 | $42.19 | $72.64 | |
| Total assets | $28.27 | $66.31 | $107.73 | $102.29 |
| Current liabilities | ||||
| Accounts payable | $3.18 | $2.17 | $1.78 | $7.38 |
| Deferred revenue | ||||
| Short long term debt | $17.65 | $4.43 | $5 | $1.71 |
| Total current liabilities | $31.89 | $12.64 | $17.01 | $31.9 |
| Long term debt | $3.24 | $15.98 | $21.59 | $25.12 |
| Total noncurrent liabilities | $3.28 | $20.68 | $21.61 | $25.12 |
| Total debt | $20.88 | $25.09 | $26.59 | $26.84 |
| Total liabilities | $35.18 | $33.32 | $38.62 | $57.02 |
| Shareholders' equity | ||||
| Retained earnings | -$436.68 | -$392.08 | -$349.73 | -$304.09 |
| Other shareholder equity | -$0 | -$0.13 | -$0.06 | -$0 |
| Total shareholder equity | -$6.9 | $32.99 | $69.11 | $45.27 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $6.87 | $5.76 | $6.98 | |
| Selling, general & administrative | $4.12 | $3.86 | $3.12 | |
| Total operating expenses | $10.99 | $9.62 | $10.1 | |
| Operating income | -$10.99 | -$9.62 | -$10.1 | |
| Income from continuing operations | ||||
| EBIT | -$9.35 | -$6.72 | -$7.31 | |
| Income tax expense | ||||
| Interest expense | $0.65 | $0.18 | $0.71 | |
| Net income | ||||
| Net income | -$10 | -$6.9 | -$8.02 | |
| Income (for common shares) | -$10 | -$6.9 | -$8.02 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.88 | $3.94 | ||
| Cost of revenue | ||||
| Gross Profit | $0.88 | $3.94 | ||
| Operating activities | ||||
| Research & development | $31.17 | $16.14 | $36.45 | $98.27 |
| Selling, general & administrative | $13.91 | $18.7 | $20.43 | $28.48 |
| Total operating expenses | $45.08 | $39.84 | $56.87 | $126.75 |
| Operating income | -$45.08 | -$39.84 | -$55.99 | -$122.81 |
| Income from continuing operations | ||||
| EBIT | -$41.68 | -$40.21 | -$43.81 | -$110.24 |
| Income tax expense | ||||
| Interest expense | $2.92 | $2.13 | $1.83 | $1.03 |
| Net income | ||||
| Net income | -$44.6 | -$42.35 | -$45.64 | -$111.27 |
| Income (for common shares) | -$44.6 | -$42.35 | -$45.64 | -$111.27 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$10 | -$6.9 | -$8.02 | |
| Operating activities | ||||
| Depreciation | $0.15 | $0.15 | $0.15 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.29 | $0.98 | $0.8 | |
| Total cash flows from operations | -$8.94 | -$7.97 | -$6.01 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$16.44 | -$98.24 | $10.39 | |
| Total cash flows from investing | -$130.04 | -$16.44 | -$98.24 | $10.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $30.54 | $115.59 | $0 | |
| Net borrowings | -$2.27 | -$2.32 | -$1.83 | |
| Total cash flows from financing | $166.59 | $34.96 | $106.58 | -$1.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $5.7 | $9.58 | $0.38 | $2.47 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$44.6 | -$42.35 | -$45.64 | -$111.27 |
| Operating activities | ||||
| Depreciation | $0.64 | $1.49 | $1.64 | $1.69 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.47 | $5.72 | $9.48 | $12.46 |
| Total cash flows from operations | -$36.1 | -$37.54 | -$48.18 | -$99.69 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.03 | -$0.48 | |
| Investments | $35.64 | $30.08 | -$73.39 | |
| Total cash flows from investing | $35.64 | $30.07 | -$73.42 | -$0.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.24 | $62.59 | $142.2 | |
| Net borrowings | -$2.87 | -$0.53 | $0.06 | $18.71 |
| Total cash flows from financing | -$2.82 | -$0.53 | $60.82 | $154.87 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.28 | -$8 | -$60.78 | $54.7 |
News
Fundamentals
| Market cap | $65.65M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 12.18M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.29 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -5.09 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 13.84 |
| Quick ratio | N/A |